Flash note: Pipeline candidate now in Roche's hands
Roche is to acquire Adheron Therapeutics for $105m upfront (+ $475m in milestones). The Swiss pharma giant will therefore be responsible for further developing Adheron’s Phase I asset SDP051, an anti-cadherin-11 monoclonal antibody that was fully humanised using Abzena's Composite Human Antibody technology. SDP051 has the potential to treat inflammatory/autoimmune diseases, such as rheumatoid arthritis and fibrotic disease (eg NASH), large target markets. We estimate that Abzena will receive a small royalty (~1%) on successful commercialisation of SDP051, and view the Roche deal as validation of the product/technology combination and commercial opportunity.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.